BIOHAVEN LTD (BHVN)

VGG1110E1079 - Common Stock

46.7  +1.51 (+3.34%)

Fundamental Rating

2

Taking everything into account, BHVN scores 2 out of 10 in our fundamental rating. BHVN was compared to 565 industry peers in the Biotechnology industry. BHVN has a great financial health rating, but its profitability evaluates not so good. BHVN has a expensive valuation and it also scores bad on growth.



0

1. Profitability

1.1 Basic Checks

In the past year BHVN has reported negative net income.
BHVN had a negative operating cash flow in the past year.
BHVN had negative earnings in each of the past 5 years.
In the past 5 years BHVN always reported negative operating cash flow.

1.2 Ratios

BHVN has a worse Return On Assets (-128.14%) than 81.82% of its industry peers.
Looking at the Return On Equity, with a value of -194.56%, BHVN is doing worse than 68.45% of the companies in the same industry.
Industry RankSector Rank
ROA -128.14%
ROE -194.56%
ROIC N/A
ROA(3y)-105.39%
ROA(5y)-115.24%
ROE(3y)-272.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BHVN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

7

2. Health

2.1 Basic Checks

BHVN has more shares outstanding than it did 1 year ago.
BHVN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BHVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

BHVN has an Altman-Z score of 7.32. This indicates that BHVN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BHVN (7.32) is better than 83.42% of its industry peers.
There is no outstanding debt for BHVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.32
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 3.27 indicates that BHVN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.27, BHVN is doing worse than 60.78% of the companies in the same industry.
A Quick Ratio of 3.27 indicates that BHVN has no problem at all paying its short term obligations.
BHVN has a Quick ratio (3.27) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.27
Quick Ratio 3.27

1

3. Growth

3.1 Past

The earnings per share for BHVN have decreased strongly by -32.23% in the last year.
EPS 1Y (TTM)-32.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-175.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BHVN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.37% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-60.03%
EPS Next 2Y-6.76%
EPS Next 3Y0.79%
EPS Next 5Y14.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BHVN. In the last year negative earnings were reported.
Also next year BHVN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.76%
EPS Next 3Y0.79%

0

5. Dividend

5.1 Amount

BHVN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BIOHAVEN LTD

NYSE:BHVN (11/22/2024, 11:54:03 AM)

46.7

+1.51 (+3.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.60B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -128.14%
ROE -194.56%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.27
Quick Ratio 3.27
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-32.23%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-60.03%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y